Cronos Group Inc. (CRON) stock

CRONNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 15/306% below fair value

$3.41−0.04 (-1.16%)

Close on Nov 12, 2026Market cap $1.26BP/E 20.1Yield –

Cronos EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Cronos's EV/EBITDA was 93.3× on Nov 11, 2026.

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	93.3×	+91.2
2023	Jan 31, 2023	2.1×	−0.3
2022	Dec 30, 2022	2.3×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CRON.

Revenue growth55.8% · median 6.2%

Gross margin46.6% · median 35.6%

Operating margin3.4% · median -1.5%

Net margin28.0% · median -48.1%

Advertisement
300 × 250

See a number that looks wrong?